How to Read Peptide Research: Understanding Study Design, Animal vs Human Dosing, and Effect Sizes

The peptide research landscape is growing rapidly, but not all studies carry equal weight. For researchers, clinicians, and informed readers trying to make sense of published findings, understanding how to evaluate study design, dosing context, and reported effect sizes is essential. This guide, compiled by the Peptide Register as part of its educational reference mission, outlines the key factors to consider when reading peptide literature.

Study Design Hierarchy: Why the Type of Evidence Matters

Not all evidence is created equal. The standard evidence hierarchy places systematic reviews and meta-analyses of randomised controlled trials (RCTs) at the top, followed by individual RCTs, cohort studies, case-control studies, case series, and finally expert opinion or mechanistic reasoning. Most peptide research falls somewhere in the middle to lower tiers of this hierarchy.

A large proportion of published peptide research relies on animal models or in vitro cell studies rather than human clinical trials. Animal studies in peptide research frequently use rodent models, which may not accurately predict human pharmacokinetics, metabolism, or efficacy. This does not mean animal data is worthless; it provides important mechanistic insights. However, findings from rodent studies should never be treated as direct evidence of effects in humans.

When evaluating any peptide study, check for: randomisation (were subjects randomly assigned to treatment and control groups?), blinding (did researchers and/or subjects know who received the active compound?), control groups (was there a placebo or active comparator?), and sample size (how many subjects were included?). Many peptide studies that circulate widely online involve fewer than 30 subjects, which limits statistical power and the reliability of conclusions. For context on how different peptides have been studied, the Peptide Register maintains structured peptide profiles that catalogue available evidence by type.

Translating Animal Doses to Human Equivalent Doses

One of the most common errors in interpreting peptide research is reading an animal dose as directly applicable to humans. Allometric scaling is required to convert doses between species because metabolic rate, body surface area, and drug clearance differ substantially across organisms. The FDA has published guidance on estimating human equivalent doses (HED) from animal data, using body surface area normalisation factors.

The standard FDA conversion factor from mouse to human is approximately 12.3, meaning a mouse dose in mg/kg is divided by 12.3 to estimate a rough human equivalent dose in mg/kg. For rats, the conversion factor is approximately 6.2. These are approximations only and do not account for species-specific differences in receptor binding, peptide half-life, or route of administration. Peptide bioavailability varies significantly by delivery route, as explored in more detail in our post on how subcutaneous, oral, and nasal delivery routes compare.

It is important to note that allometric scaling provides only a rough starting estimate, not a validated therapeutic dose. Regulatory agencies require dedicated Phase I human pharmacokinetic trials before any dose can be considered appropriate for clinical use. Readers should be skeptical of any source presenting animal-derived doses as human protocols.

Interpreting Effect Sizes and Statistical Significance

A statistically significant result does not automatically mean a clinically meaningful one. Statistical significance, typically defined as p < 0.05, indicates only that an observed difference is unlikely to be due to chance alone. Effect size, by contrast, quantifies how large the observed difference actually is.

Cohen's d is a commonly used effect size metric in peptide studies: values around 0.2 are considered small, 0.5 medium, and 0.8 or above large. A study may report a statistically significant finding with p < 0.01 but show only a small effect size, suggesting the real-world relevance may be limited. Conversely, some studies with modest p-values may show large effect sizes but lack adequate sample sizes to reach conventional significance thresholds.

Confidence intervals provide additional context beyond p-values alone. Wide confidence intervals in peptide studies often indicate high variability or small sample sizes, reducing certainty about the true effect. Researchers should look for studies that report both p-values and confidence intervals alongside effect size measures.

Red Flags and Best Practices for Critical Reading

Several warning signs should prompt additional scrutiny when evaluating peptide research. Studies funded exclusively by the peptide manufacturer without independent replication warrant caution. Research published only in predatory or low-impact journals may not have undergone rigorous peer review. Claims extrapolated from a single small study without replication remain preliminary at best.

Approximately 85% of published peptide studies catalogued by the Peptide Register as of early 2026 involve animal models or in vitro data rather than human RCTs. This statistic underscores the early stage of evidence for many peptides discussed online. For a broader perspective on what is known about peptide safety limitations, see our overview of peptide safety research, side effects, and long-term risks.

Best practices for reading peptide research include: checking the study population (animal vs human), noting sample size and statistical methodology, examining whether findings have been independently replicated, reviewing the funding source and potential conflicts of interest, and distinguishing between surrogate endpoints and clinically relevant outcomes. The Peptide Register exists to help researchers and clinicians navigate this evidence landscape with structured, referenced profiles and regulatory context across jurisdictions.

Understanding how to critically evaluate peptide studies is the foundation of informed interpretation. Without this skill, it is easy to overstate the strength of preliminary findings or misapply animal data to human contexts.